At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 81 enrolled
Drug / intervention
Prednisone +2 moredrug
Likely dose
Prednisone 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TNF-alpha Antagonists for Acute Exacerbations of COPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial
In Brief
A Phase 3 clinical trial evaluating Prednisone, Etanercept, and 1 other intervention for COPD Exacerbation. Completed, enrolled 81 participants.
Detailed Summary
The purpose of this study is to determine whether treatment with antibiotics plus a TNFalpha antagonist will provide more effective treatment for acute COPD exacerbation compared to the current standard treatment of antibiotics plus prednisone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD Exacerbation
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
First PostedNov 2008
Primary CompletionAug 2011
Study CompletionOct 2011
TodayJul 2026
First PostedNov 13, 2008
Enrollment StartNov 1, 2008
Primary CompletionAug 1, 2011
Study CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.6 years ago
Interventions
Prednisonedrug
prednisone 40 mg daily for 10 days or placebo prednisone
Etanerceptdrug
etanercept 50 mg subcutaneous given on the day of randomization and one week later or placebo subcutaneous injection
levofloxacindrug
Levofloxacin 750 mg daily for 10 days.